News Novo posts strong performance, but US pricing pressure grows Pharmacy benefit managers and arrival of biosimilars making life difficult for diabetes companies
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Novo Nordisk buoyed by Victoza cardiovascular results Largest and longest trial ever conducted by the company
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.